大族激光(002008.SZ)拉昇漲近5% 中標新能源電池業務11.94億元
格隆匯12月30日丨大族激光(002008.SZ)拉昇漲近5%報40.62元,最新總市值434億元。公司昨晚公吿,近期陸續收到主要客户寧德時代及其控股子公司中標通知。中標項目為鋰電池生產設備。自2020年9月18日至本公吿披露日,公司收到寧德時代及其控股子公司中標通知累計11.94億元人民幣。其中,已簽署正式訂單合同的中標設備金額為9.50億元,尚未簽署正式訂單合同的中標設備金額為2.44億元。此次中標有利於公司及子公司在新能源電池領域的業務拓展,提高公司收入規模及盈利能力。此次中標設備的交付期主要集中在2021年度,預計將對公司2021年度的經營業績產生積極影響。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.